Henri Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henri Schmidt has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arutha Kulasinghe
The University of Queensland
1 shared publication - Chamindie Punyadeera
Institute For Biomedicine and Glycomics (IBG) Griffith University Queensland Australia
1 shared publication - Elisa Mokany
SpeeDx Pty. Ltd., National Innovation Centre, Australian Technology Park, Eveleigh Sydney 2015, New South Wales, Australia
1 shared publication - Lit Yeen Tan
SpeeDx Pty. Ltd., National Innovation Centre, Australian Technology Park, Eveleigh Sydney 2015, New South Wales, Australia
1 shared publication - Lizbeth Kenny
School of Medicine The University of Queensland Brisbane Australia
1 shared publication - Richard James Nigel Allcock
School of Biomedical Sciences, University of Western Australia, Perth 6009, Australia
1 shared publication
Latest Publications
- Open Access
- 29 November 2018
- Published by MDPI AG in Diagnostics
- Vol. 8 (4) , 79
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer
Background: PIK3CA pathways are the most frequently mutated oncogenic pathway in head and neck squamous cell carcinoma (HNSCC), including virally driven HNCs. PIK3CA is involved in the PI3K-PTEN-mTOR signalling pathway. PIK3CA has been implicated in HNSCC progression and PIK3CA mutations may serve as predictive biomarkers for therapy selection. Circulating tumour DNA (ctDNA) derived from necrotic and apoptotic tumour cells are thought to harbour tumour-specific genetic alterations. As such, the detection of PIK3CA alterations detected by ctDNA holds promise as a potential biomarker in HNSCC. Methods: Blood samples from treatment naïve HNSCC patients (n = 29) were interrogated for a commonly mutated PIK3CA hotspot mutation using low cost allele-specific Plex-PCRTM technology. Results: In this pilot, cross sectional study, PIK3CA E545K mutation was detected in the plasma samples of 9/29 HNSCC patients using the Plex-PCRTM technology. Conclusion: The results of this pilot study support the notion of using allele-specific technologies for cost-effective testing of ctDNA, and further assert the potential utility of ctDNA in HNSCC.
- 29 November 2018
- Published by MDPI AG in Diagnostics
- Vol. 8 (4) , 79
Open AccessA Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer
Background: PIK3CA pathways are the most frequently mutated oncogenic pathway in head and neck squamous cell carcinoma (HNSCC), including virally driven HNCs. PIK3CA is involved in the PI3K-PTEN-mTOR signalling pathway. PIK3CA has been implicated in HNSCC progression and PIK3CA mutations may serve as predictive biomarkers for therapy selection. Circulating tumour DNA (ctDNA) derived from necrotic and apoptotic tumour cells are thought to harbour tumour-specific genetic alterations. As such, the detection of PIK3CA alterations detected by ctDNA holds promise as a potential biomarker in HNSCC. Methods: Blood samples from treatment naïve HNSCC patients (n = 29) were interrogated for a commonly mutated PIK3CA hotspot mutation using low cost allele-specific Plex-PCRTM technology. Results: In this pilot, cross sectional study, PIK3CA E545K mutation was detected in the plasma samples of 9/29 HNSCC patients using the Plex-PCRTM technology. Conclusion: The results of this pilot study support the notion of using allele-specific technologies for cost-effective testing of ctDNA, and further assert the potential utility of ctDNA in HNSCC.